Navigation Links
Pitt team finds melatonin delays ALS symptom onset and death in mice
Date:4/24/2013

Melatonin injections delayed symptom onset and reduced mortality in a mouse model of the neurodegenerative condition amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, according to a new study by researchers at the University of Pittsburgh School of Medicine. In a report published online ahead of print in the journal Neurobiology of Disease, the team revealed that receptors for melatonin are found in the nerve cells, a finding that could launch novel therapeutic approaches.

Annually about 5,000 people are diagnosed with ALS, which is characterized by progressive muscle weakness and eventual death due to the failure of respiratory muscles, said senior investigator Robert Friedlander, M.D., UPMC Endowed Professor of neurosurgery and neurobiology and chair, Department of Neurological Surgery, Pitt School of Medicine. But the causes of the condition are not well understood, thwarting development of a cure or even effective treatments.

Melatonin is a naturally occurring hormone that is best known for its role in sleep regulation. After screening more than a thousand FDA-approved drugs several years ago, the research team determined that melatonin is a powerful antioxidant that blocks the release of enzymes that activate apoptosis, or programmed cell death.

"Our experiments show for the first time that a lack of melatonin and melatonin receptor 1, or MT1, is associated with the progression of ALS," Dr. Friedlander said. "We saw similar results in a Huntington's disease model in an earlier project, suggesting similar biochemical pathways are disrupted in these challenging neurologic diseases."

Hoping to stop neuron death in ALS just as they did in Huntington's, the research team treated mice bred to have an ALS-like disease with injections of melatonin or with a placebo. Compared to untreated animals, the melatonin group developed symptoms later, survived longer, and had less degeneration of motor neurons in the spinal cord.

"Much more work has to be done to unravel these mechanisms before human trials of melatonin or a drug akin to it can be conducted to determine its usefulness as an ALS treatment," Dr. Friedlander said. "I suspect that a combination of agents that act on these pathways will be needed to make headway with this devastating disease."


'/>"/>

Contact: Anita Srikameswaran
SrikamAV@upmc.edu
412-578-9193
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related biology news :

1. Rescue me: New study finds animals do recover from neglect
2. Gene sequencing project finds new mutations to blame for a majority of brain tumor subtype
3. Exercise or make dinner? Study finds adults trade one healthy act for another
4. Sustainable fishing certification too lenient and discretionary, study finds
5. Couch potatoes may be genetically predisposed to being lazy, MU study finds
6. Notre Dame study finds Asian carp DNA not widespread in the Great Lakes
7. Marriage can threaten health: Study finds satisfied newlyweds more likely to gain weight
8. Southern California sagebrush better suited to climate change, UCI study finds
9. Pitt team finds immunity protein that ramps up inflammation, and agents that can block it
10. Study finds strong genetic component to childhood obesity
11. Do I know you? Memory patterns help us recall the social webs we weave, finds new Cornell study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 8.8% over the next decade to reach approximately $14.21 ... market estimates and forecasts for all the given segments on global ...
(Date:3/22/2017)... 2017 Vigilant Solutions , a vehicle ... agencies, announced today the appointment of retired FBI special ... safety business development. Mr. Sheridan brings more ... a focus on the aviation transportation sector, to his ... Mr. Sheridan served as the Aviation Liaison Agent Coordinator ...
(Date:3/16/2017)... , March 16, 2017 CeBIT 2017 - Against identity fraud ... Continue Reading ... Used combined in one project, multi-biometric solutions provide a ... Used combined ... ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... ... 2017 , ... Proscia Inc., a data ... has the potential to eliminate subjectivity in the detection and classification of breast ... of the 2017 ISBI CAMELYON Digital Pathology Challenge, organized by the ...
(Date:4/27/2017)... ... April 27, 2017 , ... This month Quorum Review ... that simplifies research studies, accelerates study startup, and improves participant engagement. Developed by ... the first and only IRB-integrated eConsent solution . , “Our mission at ...
(Date:4/27/2017)... ... April 27, 2017 , ... During the course of this ... for 1,25-Dihydroxyvitamin D can enhance clinical practice. Participants will learn the medical indications ... , Dr. Gregory Plotnikoff, senior consultant with Minnesota Personalized Medicine, will be the ...
(Date:4/27/2017)... , ... April 27, 2017 ... ... announced a comprehensive rebrand and a name change to Fluence Analytics. ... and laboratory monitoring of polymer and biopharmaceutical manufacturing processes and R&D applications. ...
Breaking Biology Technology: